UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $52.42 Million Stake in Inari Medical, Inc. (NASDAQ:NARI)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its position in Inari Medical, Inc. (NASDAQ:NARI) by 3.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,270,991 shares of the company’s stock after selling 48,011 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 2.17% of Inari Medical worth $52,416,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Point72 Asset Management L.P. grew its position in Inari Medical by 113.3% in the second quarter. Point72 Asset Management L.P. now owns 1,481,283 shares of the company’s stock worth $71,324,000 after acquiring an additional 786,691 shares in the last quarter. Armistice Capital LLC boosted its holdings in Inari Medical by 353.1% in the second quarter. Armistice Capital LLC now owns 1,009,252 shares of the company’s stock worth $48,595,000 after purchasing an additional 786,501 shares in the last quarter. Jennison Associates LLC increased its position in Inari Medical by 63.2% during the third quarter. Jennison Associates LLC now owns 1,576,641 shares of the company’s stock worth $65,021,000 after buying an additional 610,468 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in Inari Medical by 101.3% during the third quarter. The Manufacturers Life Insurance Company now owns 795,099 shares of the company’s stock valued at $32,790,000 after buying an additional 400,198 shares in the last quarter. Finally, First Light Asset Management LLC lifted its position in shares of Inari Medical by 120.8% in the second quarter. First Light Asset Management LLC now owns 472,384 shares of the company’s stock worth $22,745,000 after buying an additional 258,444 shares during the last quarter. Institutional investors own 90.98% of the company’s stock.

Wall Street Analyst Weigh In

NARI has been the topic of a number of recent analyst reports. Leerink Partners began coverage on Inari Medical in a research note on Tuesday, September 3rd. They issued a “market perform” rating and a $47.00 price objective on the stock. Robert W. Baird lifted their price target on shares of Inari Medical from $66.00 to $67.00 and gave the company an “outperform” rating in a research report on Tuesday, October 29th. Canaccord Genuity Group upped their price objective on shares of Inari Medical from $71.00 to $74.00 and gave the stock a “buy” rating in a report on Tuesday, October 29th. Needham & Company LLC reiterated a “hold” rating on shares of Inari Medical in a report on Tuesday, October 29th. Finally, Truist Financial boosted their target price on shares of Inari Medical from $46.00 to $50.00 and gave the stock a “hold” rating in a research report on Tuesday, October 29th. Six investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $58.89.

Inari Medical Price Performance

NASDAQ NARI opened at $51.55 on Wednesday. The company’s fifty day moving average is $46.67 and its two-hundred day moving average is $47.62. Inari Medical, Inc. has a 52-week low of $36.73 and a 52-week high of $67.13. The firm has a market capitalization of $3.02 billion, a price-to-earnings ratio of -38.18 and a beta of 0.97.

Insider Buying and Selling

In other news, Director William Hoffman sold 60,000 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $51.16, for a total transaction of $3,069,600.00. Following the sale, the director now directly owns 501,233 shares in the company, valued at approximately $25,643,080.28. The trade was a 10.69 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Mitch C. Hill sold 3,000 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $45.13, for a total value of $135,390.00. Following the completion of the transaction, the chief financial officer now directly owns 179,600 shares of the company’s stock, valued at approximately $8,105,348. This trade represents a 1.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 186,000 shares of company stock valued at $8,990,990 over the last three months. 10.60% of the stock is owned by corporate insiders.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.